Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Nuo Therapeutics, Inc. (AURX)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
42.3
|
M
| |
|
|
| Market cap: |
$4.2
|
k
| |
|
|
|
Net cash:
|
$344.4
|
k
| |
$0.01
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| Revenues | 0.0 | 0.0 | 0.1 | 1.4 | 0.7 | 11.5 | 7.8 | 11.6 |
| Revenue growth | | -100.0% | -89.3% | 90.1% | | 48.3% | -32.9% | 9.5% |
| Cost of goods sold | 0.0 | 0.0 | 0.1 | 0.2 | 2.9 | 8.0 | 6.8 | 8.5 |
| Gross profit | 0.0 | 0.0 | 0.0 | 1.2 | -2.2 | 3.5 | 1.0 | 3.1 |
| Gross margin | | | 21.6% | 88.1% | -304.0% | 30.8% | 12.8% | 26.9% |
| Selling, general and administrative | | | | | | | | 15.3 |
| Sales and marketing | | | 0.0 | 0.1 | 0.7 | 6.2 | 5.8 | |
| Research and development | | | 0.2 | 0.6 | 1.3 | 2.6 | 4.0 | 3.8 |
| General and administrative | 0.1 | 0.4 | 0.8 | 2.0 | 3.8 | 9.0 | 9.9 | 7.9 |
| EBITA | -0.1 | -0.4 | -1.0 | -1.5 | -5.4 | -14.3 | -18.8 | -18.1 |
| EBITA margin | | | -663.0% | -109.8% | -746.6% | -124.0% | -242.7% | -156.4% |
| Amortization of intangibles | | | | | 0.9 | | | |
| EBIT | -0.1 | -0.4 | -1.0 | -1.5 | -6.2 | -14.3 | -18.8 | -18.1 |
| EBIT margin | | | -663.0% | -109.8% | -864.7% | -124.0% | -242.7% | -156.4% |
| Pre-tax income | -0.1 | -0.1 | -1.2 | -1.5 | -15.0 | -52.9 | -18.9 | -20.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | | |
| Net income | -0.1 | -0.1 | -1.2 | -1.5 | -15.0 | -52.8 | -18.9 | -20.2 |
| Net margin | | | -817.4% | -112.5% | -2077.4% | -458.8% | -243.3% | -175.0% |
| |
| Diluted EPS | $0.00 | $0.00 | ($0.05) | ($0.07) | ($1.02) | ($0.42) | ($0.16) | ($0.20) |
| Shares outstanding (diluted) | 30.3 | 27.3 | 23.7 | 23.3 | 14.6 | 126.0 | 120.5 | 103.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|